Sun Pharmaceutical Industries Ltd has informed BSE that one of the Company's wholly-owned subsidiaries has voluntarily

Sun Pharmaceutical Industries Ltd has informed BSE that one of the Company's wholly-owned subsidiaries has voluntarily

Sun Pharmaceutical Industries Ltd announced today the successful completion of its acquisition of InSite Vision Incorporated.

Sun Pharmaceutical Industries Ltd announced today the successful completion of its acquisition of InSite Vision Incorporated.

Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,

Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,

Sun Pharmaceutical Industries Ltd has announced the following consolidated results for the quarter ended June 30, 2016:

Sun Pharmaceutical Industries Ltd has announced the following consolidated results for the quarter ended June 30, 2016:

India’s largest drugmaker Sun Pharmaceutical Industries Ltd said it had received a warning letter from the US Food and Drug Administration for violating manufacturing standards at its Halol plant in western India. The warning indicates the agency is not satisfied with the remedial measures Sun Pharma has been taking at the plant since last September …

India’s largest drugmaker Sun Pharmaceutical Industries Ltd said it had received a warning letter from the US Food and Drug Administration for violating manufacturing standards at its Halol plant in western India. The warning indicates the agency is not satisfied with the remedial measures Sun Pharma has been taking at the plant since last September …

As part of its business strategy to build a meaningful & differentiating presence in Global Oncology Therapy market, Sun Pharma,

As part of its business strategy to build a meaningful & differentiating presence in Global Oncology Therapy market, Sun Pharma,

Chennai:   Drug major Sun Pharmaceutical Industries Ltd on Monday announced the launch of ready-to-administer cancer drug Gemcitabine InfuSMART in Europe. In a statement, the company said InfuSMART is a technology in which oncology/cancer products were developed in a ready-to-administer bag. "Until now, compounding of oncology products was done at compounding centres or compounded in hospi..  Read More

Chennai: Drug major Sun Pharmaceutical Industries Ltd on Monday announced the launch of ready-to-administer cancer drug Gemcitabine InfuSMART in Europe. In a statement, the company said InfuSMART is a technology in which oncology/cancer products were developed in a ready-to-administer bag. "Until now, compounding of oncology products was done at compounding centres or compounded in hospi.. Read More

Sun Pharmaceutical Industries Ltd posted a net profit of Rs. 17136.90 million for the quarter ended March 31, 2016 where as the same was at Rs. 8892.40 - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/sun-pharma-q4-net-profit-at-rs1713690-mn.html#sthash.V5x4pKck.dpuf

Sun Pharmaceutical Industries Ltd posted a net profit of Rs. 17136.90 million for the quarter ended March 31, 2016 where as the same was at Rs. 8892.40 - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/sun-pharma-q4-net-profit-at-rs1713690-mn.html#sthash.V5x4pKck.dpuf

Sun Pharmaceutical Industries Ltd ended 2.8% higher at Rs. 777.3 after the US drug regulator gave a green signal to the company’s generic Gleevec drug.

Sun Pharmaceutical Industries Ltd ended 2.8% higher at Rs. 777.3 after the US drug regulator gave a green signal to the company’s generic Gleevec drug.

Sun Pharma announces USFDA approval for generic Namenda® tablets	   	Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.’s Namenda 5 mg and 10 mg tablets.

Sun Pharma announces USFDA approval for generic Namenda® tablets Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.’s Namenda 5 mg and 10 mg tablets.

Pinterest
Search